Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Matthew J. Frank, MD, PhD, discusses remaining questions regarding treatment sequencing following preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.
Matthew Frank, MD, PhD, discusses the rationale for evaluating CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma, important safety and efficacy data with this approach, next steps for this research, and how continued efforts may shed needed light on sequencing in this space.
The FDA has granted fast track designation IVS-3001 for use as a potential therapeutic option in patients with renal cell carcinoma.
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.
Pittsburgh, Pa. (PRWEB) July 27, 2023 -- The family of Robert J. Granata, a cancer survivor and Michigan entrepreneur, has donated $1 million to support